federal_register: 2013-28394

All Federal Register documents (rules, proposed rules, notices, presidential documents) from 1994 to present. Nearly 1M documents with full-text search.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

document_number title type abstract publication_date pub_year pub_month html_url pdf_url agency_names agency_ids excerpts
2013-28394 Draft Guidance for Industry on Bioequivalence Recommendations for Fluticasone Propionate; Salmeterol Xinafoate; Reopening of the Comment Period Notice The Food and Drug Administration (FDA) is reopening the comment period for the notice of availability entitled "Draft Guidance for Industry on Bioequivalence Recommendations for Fluticasone Propionate; Salmeterol Xinafoate", published in the Federal Register of September 10, 2013 (78 FR 55263). In that notice, FDA requested public comment on the draft guidance. FDA is reopening the comment period due to the inability of some commenters to submit comments through the www.regulations.gov Web site from November 4, 2013, through November 13, 2013, due to technical difficulties. 2013-11-27 2013 11 https://www.federalregister.gov/documents/2013/11/27/2013-28394/draft-guidance-for-industry-on-bioequivalence-recommendations-for-fluticasone-propionate-salmeterol https://www.govinfo.gov/content/pkg/FR-2013-11-27/pdf/2013-28394.pdf Health and Human Services Department; Food and Drug Administration 221,199 The Food and Drug Administration (FDA) is reopening the comment period for the notice of availability entitled "Draft Guidance for Industry on Bioequivalence Recommendations for Fluticasone Propionate; Salmeterol Xinafoate", published in the Federal...

Links from other tables